{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:01:07Z","timestamp":1790870467685,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071961"],"award-info":[{"award-number":["82071961"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key Scientific Research Program for Yong Scholars in Fujian","award":["2021ZQNZD016"],"award-info":[{"award-number":["2021ZQNZD016"]}]},{"name":"Fujian Natural Science Foundation for Distinguished Yong Scholars","award":["2022D005"],"award-info":[{"award-number":["2022D005"]}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"crossref","award":["MOH-001388-00, CG21APR1005"],"award-info":[{"award-number":["MOH-001388-00, CG21APR1005"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001459","name":"Singapore Ministry of Education","doi-asserted-by":"crossref","award":["MOE-000387-00"],"award-info":[{"award-number":["MOE-000387-00"]}],"id":[{"id":"10.13039\/501100001459","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"crossref","award":["NRF-000352-00"],"award-info":[{"award-number":["NRF-000352-00"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001352","name":"the National University of Singapore","doi-asserted-by":"crossref","award":["NUHSRO\/2020\/133\/Startup\/08, NUHSRO\/2023\/008\/NUSMed\/TCE\/LOA, NUHSRO\/2021\/034\/TRP\/09\/Nanomedicine"],"award-info":[{"award-number":["NUHSRO\/2020\/133\/Startup\/08, NUHSRO\/2023\/008\/NUSMed\/TCE\/LOA, NUHSRO\/2021\/034\/TRP\/09\/Nanomedicine"]}],"id":[{"id":"10.13039\/501100001352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00259-024-06874-9","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T08:01:51Z","timestamp":1723708911000},"page":"247-259","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Development of [177Lu]Lu-LNC1010 for peptide receptor radionuclide therapy of nasopharyngeal carcinoma"],"prefix":"10.1007","volume":"52","author":[{"given":"Jianhao","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhen","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyi","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangfan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qicong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changjing","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9101-8884","authenticated-orcid":false,"given":"Haojun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,15]]},"reference":[{"key":"6874_CR1","doi-asserted-by":"publisher","unstructured":"Zhang Y, Sun Y, Ma J. Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma. Cancer Commun (Lond). 2019;39:39. https:\/\/doi.org\/10.1186\/s40880-019-0385-5.","DOI":"10.1186\/s40880-019-0385-5"},{"key":"6874_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41467-020-20308-8","volume":"12","author":"M Lechner","year":"2021","unstructured":"Lechner M, Schartinger VH, Steele CD, Nei WL, Ooft ML, Schreiber L-M, et al. Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy. Nat Commun. 2021;12:117. https:\/\/doi.org\/10.1038\/s41467-020-20308-8.","journal-title":"Nat Commun"},{"key":"6874_CR3","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","volume":"394","author":"Y-P Chen","year":"2019","unstructured":"Chen Y-P, Chan ATC, Le Q-T, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394:64\u201380. https:\/\/doi.org\/10.1016\/S0140-6736(19)30956-0.","journal-title":"Lancet"},{"key":"6874_CR4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"Cancer J Clin"},{"key":"6874_CR5","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1200\/JCO.20.02712","volume":"39","author":"F-H Wang","year":"2021","unstructured":"Wang F-H, Wei X-L, Feng J, Li Q, Xu N, Hu X-C, et al. Efficacy, Safety, and Correlative Biomarkers of Toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02). J Clin Oncol. 2021;39:704\u201312. https:\/\/doi.org\/10.1200\/JCO.20.02712.","journal-title":"J Clin Oncol"},{"key":"6874_CR6","doi-asserted-by":"publisher","first-page":"364","DOI":"10.2967\/jnumed.112.111724","volume":"54","author":"D Wild","year":"2013","unstructured":"Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, et al. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET\/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nuclear Medicine: Official Publication Soc Nuclear Med. 2013;54:364\u201372. https:\/\/doi.org\/10.2967\/jnumed.112.111724.","journal-title":"J Nuclear Medicine: Official Publication Soc Nuclear Med"},{"key":"6874_CR7","doi-asserted-by":"publisher","first-page":"756","DOI":"10.2967\/jnumed.116.185587","volume":"58","author":"M Barrio","year":"2017","unstructured":"Barrio M, Czernin J, Fanti S, Ambrosini V, Binse I, Du L, et al. The impact of somatostatin receptor-Directed PET\/CT on the management of patients with neuroendocrine tumor: a systematic review and Meta-analysis. J Nuclear Medicine: Official Publication Soc Nuclear Med. 2017;58:756\u201361. https:\/\/doi.org\/10.2967\/jnumed.116.185587.","journal-title":"J Nuclear Medicine: Official Publication Soc Nuclear Med"},{"key":"6874_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s00259-008-0944-5","volume":"36","author":"M Miederer","year":"2009","unstructured":"Miederer M, Seidl S, Buck A, Scheidhauer K, Wester H-J, Schwaiger M, et al. Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET\/CT. Eur J Nucl Med Mol Imaging. 2009;36:48\u201352. https:\/\/doi.org\/10.1007\/s00259-008-0944-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6874_CR9","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1007\/s00259-021-05587-7","volume":"49","author":"L Zhao","year":"2022","unstructured":"Zhao L, Pang Y, Wang Y, Chen J, Zhuang Y, Zhang J, et al. Somatostatin receptor imaging with [68Ga]Ga-DOTATATE positron emission tomography\/computed tomography (PET\/CT) in patients with nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2022;49:1360\u201373. https:\/\/doi.org\/10.1007\/s00259-021-05587-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6874_CR10","doi-asserted-by":"publisher","first-page":"394","DOI":"10.2967\/jnumed.123.266183","volume":"65","author":"L Zhao","year":"2024","unstructured":"Zhao L, Pang Y, Fang J, Chen J, Zhou Y, Sun L, et al. Design, preclinical evaluation, and clinical translation of 68Ga-FAPI-LM3, a Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma. J Nuclear Medicine: Official Publication Soc Nuclear Med. 2024;65:394\u2013401. https:\/\/doi.org\/10.2967\/jnumed.123.266183.","journal-title":"J Nuclear Medicine: Official Publication Soc Nuclear Med"},{"key":"6874_CR11","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1097\/RLU.0000000000002788","volume":"44","author":"W Zhu","year":"2019","unstructured":"Zhu W, Zhang J, Singh A, Kulkarni HR, Baum RP. Metastatic nasopharyngeal carcinoma treated with intraarterial combined with intravenous peptide receptor Radionuclide Therapy. Clin Nucl Med. 2019;44:989\u201390. https:\/\/doi.org\/10.1097\/RLU.0000000000002788.","journal-title":"Clin Nucl Med"},{"key":"6874_CR12","doi-asserted-by":"publisher","first-page":"735","DOI":"10.7150\/thno.23491","volume":"8","author":"R Tian","year":"2018","unstructured":"Tian R, Jacobson O, Niu G, Kiesewetter DO, Wang Z, Zhu G, et al. Evans Blue Attachment enhances somatostatin receptor Subtype-2 imaging and Radiotherapy. Theranostics. 2018;8:735\u201345. https:\/\/doi.org\/10.7150\/thno.23491.","journal-title":"Theranostics"},{"key":"6874_CR13","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s00259-018-4096-y","volume":"46","author":"J Zang","year":"2019","unstructured":"Zang J, Fan X, Wang H, Liu Q, Wang J, Li H, et al. First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:148\u201358. https:\/\/doi.org\/10.1007\/s00259-018-4096-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6874_CR14","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2967\/jnumed.120.248658","volume":"62","author":"Q Liu","year":"2021","unstructured":"Liu Q, Zang J, Sui H, Ren J, Guo H, Wang H, et al. Peptide receptor Radionuclide Therapy of late-stage neuroendocrine tumor patients with multiple cycles of 177Lu-DOTA-EB-TATE. J Nuclear Medicine: Official Publication Soc Nuclear Med. 2021;62:386\u201392. https:\/\/doi.org\/10.2967\/jnumed.120.248658.","journal-title":"J Nuclear Medicine: Official Publication Soc Nuclear Med"},{"key":"6874_CR15","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1021\/acs.bioconjchem.8b00341","volume":"29","author":"N Bandara","year":"2018","unstructured":"Bandara N, Jacobson O, Mpoy C, Chen X, Rogers BE. Novel Structural Modification Based on Evans Blue Dye to improve pharmacokinetics of a somastostatin-receptor-based Theranostic Agent. Bioconjug Chem. 2018;29:2448\u201354. https:\/\/doi.org\/10.1021\/acs.bioconjchem.8b00341.","journal-title":"Bioconjug Chem"},{"key":"6874_CR16","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.2967\/jnumed.118.209841","volume":"59","author":"J Zhang","year":"2018","unstructured":"Zhang J, Wang H, Jacobson O, Cheng Y, Niu G, Li F, et al. Safety, Pharmacokinetics, and Dosimetry of a long-acting radiolabeled somatostatin Analog 177Lu-DOTA-EB-TATE in patients with Advanced Metastatic neuroendocrine tumors. J Nuclear Medicine: Official Publication Soc Nuclear Med. 2018;59:1699\u2013705. https:\/\/doi.org\/10.2967\/jnumed.118.209841.","journal-title":"J Nuclear Medicine: Official Publication Soc Nuclear Med"},{"key":"6874_CR17","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1021\/bc200197h","volume":"22","author":"L Lang","year":"2011","unstructured":"Lang L, Li W, Guo N, Ma Y, Zhu L, Kiesewetter DO, et al. Comparison study of [18F]FAl-NOTA-PRGD2, [18F]FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice. Bioconjug Chem. 2011;22:2415\u201322. https:\/\/doi.org\/10.1021\/bc200197h.","journal-title":"Bioconjug Chem"},{"key":"6874_CR18","doi-asserted-by":"publisher","unstructured":"Guo W, Wen X, Chen Y, Zhao T, Liu J, Tao Y, et al. Development of 177Lu-LNC1010 for peptide receptor Radionuclide Therapy in patients with metastatic neuroendocrine tumors: from preclinical research to First-in- Human, dose-escalation Stu\u200bDy. Acta Pharm Sinica B. 2024. https:\/\/doi.org\/10.1016\/j.apsb.2024.05.022.","DOI":"10.1016\/j.apsb.2024.05.022"},{"key":"6874_CR19","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1158\/1078-0432.CCR-23-1983","volume":"29","author":"H Fu","year":"2023","unstructured":"Fu H, Huang J, Zhao T, Wang H, Chen Y, Xu W, et al. Fibroblast activation protein-targeted Radioligand Therapy with 177Lu-EB-FAPI for metastatic radioiodine-refractory thyroid Cancer: first-in-Human, dose-escalation study. Clin Cancer Research: Official J Am Association Cancer Res. 2023;29:4740\u201350. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1983.","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"key":"6874_CR20","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1093\/jnci\/djr432","volume":"103","author":"Q-Y Chen","year":"2011","unstructured":"Chen Q-Y, Wen Y-F, Guo L, Liu H, Huang P-Y, Mo H-Y, et al. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. J Natl Cancer Inst. 2011;103:1761\u201370. https:\/\/doi.org\/10.1093\/jnci\/djr432.","journal-title":"J Natl Cancer Inst"},{"key":"6874_CR21","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1200\/JCO.2015.60.9347","volume":"33","author":"AWM Lee","year":"2015","unstructured":"Lee AWM, Ma BBY, Ng WT, Chan ATC. Management of nasopharyngeal carcinoma: current practice and future perspective. J Clin Oncol. 2015;33:3356\u201364. https:\/\/doi.org\/10.1200\/JCO.2015.60.9347.","journal-title":"J Clin Oncol"},{"key":"6874_CR22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/0021-9150(87)90019-0","volume":"65","author":"J M\u00f6lgaard","year":"1987","unstructured":"M\u00f6lgaard J, von Schenck H, Olsson AG. Alfalfa seeds lower low density lipoprotein cholesterol and apolipoprotein B concentrations in patients with type II hyperlipoproteinemia. Atherosclerosis. 1987;65:173\u20139.","journal-title":"Atherosclerosis"},{"key":"6874_CR23","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1021\/acs.bioconjchem.8b00919","volume":"30","author":"J Lau","year":"2019","unstructured":"Lau J, Jacobson O, Niu G, Lin K-S, B\u00e9nard F, Chen X. Bench to Bedside: Albumin binders for Improved Cancer Radioligand therapies. Bioconjug Chem. 2019;30:487\u2013502. https:\/\/doi.org\/10.1021\/acs.bioconjchem.8b00919.","journal-title":"Bioconjug Chem"},{"key":"6874_CR24","doi-asserted-by":"publisher","first-page":"590","DOI":"10.2967\/jnumed.116.182097","volume":"58","author":"H Chen","year":"2017","unstructured":"Chen H, Jacobson O, Niu G, Weiss ID, Kiesewetter DO, Liu Y, et al. Novel Add-On molecule based on Evans Blue Confers Superior Pharmacokinetics and transforms drugs to Theranostic agents. J Nucl Med. 2017;58:590\u20137. https:\/\/doi.org\/10.2967\/jnumed.116.182097.","journal-title":"J Nucl Med"},{"key":"6874_CR25","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1007\/s00259-023-06229-w","volume":"50","author":"X Wen","year":"2023","unstructured":"Wen X, Xu P, Zeng X, Liu J, Du C, Zeng X, et al. Development of [177Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression. Eur J Nucl Med Mol Imaging. 2023;50:2846\u201360. https:\/\/doi.org\/10.1007\/s00259-023-06229-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6874_CR26","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s12032-015-0501-6","volume":"32","author":"J Zhang","year":"2015","unstructured":"Zhang J, Fang W, Qin T, Yang Y, Hong S, Liang W, et al. Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma. Med Oncol. 2015;32:86. https:\/\/doi.org\/10.1007\/s12032-015-0501-6.","journal-title":"Med Oncol"},{"key":"6874_CR27","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.2147\/CMAR.S193878","volume":"11","author":"L Zhao","year":"2019","unstructured":"Zhao L, Liao X, Hong G, Zhuang Y, Fu K, Chen P, et al. Mismatch repair status and high expression of PD-L1 in nasopharyngeal carcinoma. Cancer Manag Res. 2019;11:1631\u201340. https:\/\/doi.org\/10.2147\/CMAR.S193878.","journal-title":"Cancer Manag Res"},{"key":"6874_CR28","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1158\/1078-0432.CCR-12-2982","volume":"19","author":"PA Ascierto","year":"2013","unstructured":"Ascierto PA, Kalos M, Schaer DA, Callahan MK, Wolchok JD. Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Research: Official J Am Association Cancer Res. 2013;19:1009\u201320. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-2982.","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"key":"6874_CR29","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-small-cell Lung Cancer. N Engl J Med. 2015;373:1627\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1507643.","journal-title":"N Engl J Med"},{"key":"6874_CR30","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1200\/JCO.2017.77.0388","volume":"36","author":"BBY Ma","year":"2018","unstructured":"Ma BBY, Lim W-T, Goh B-C, Hui EP, Lo K-W, Pettinger A, et al. Antitumor Activity of Nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). J Clin Oncol. 2018;36:1412\u20138. https:\/\/doi.org\/10.1200\/JCO.2017.77.0388.","journal-title":"J Clin Oncol"},{"key":"6874_CR31","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1200\/JCO.2017.73.3675","volume":"35","author":"C Hsu","year":"2017","unstructured":"Hsu C, Lee SH, Ejadi S, Even C, Cohen RB, Le Tourneau C, et al. Safety and Antitumor Activity of Pembrolizumab in patients with programmed death-ligand 1-Positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study. J Clin Oncol. 2017;35:4050\u20136. https:\/\/doi.org\/10.1200\/jco.2017.73.3675.","journal-title":"J Clin Oncol"},{"key":"6874_CR32","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/s43018-021-00269-7","volume":"2","author":"AR Parikh","year":"2021","unstructured":"Parikh AR, Szabolcs A, Allen JN, Clark JW, Wo JY, Raabe M, et al. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Nat Cancer. 2021;2:1124\u201335. https:\/\/doi.org\/10.1038\/s43018-021-00269-7.","journal-title":"Nat Cancer"},{"key":"6874_CR33","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.2967\/jnumed.123.265391","volume":"64","author":"SA Esfahani","year":"2023","unstructured":"Esfahani SA, De Aguiar Ferreira C, Summer P, Mahmood U, Heidari P. Addition of peptide receptor radiotherapy to Immune Checkpoint Inhibition Therapy improves outcomes in neuroendocrine tumors. J Nuclear Medicine: Official Publication Soc Nuclear Med. 2023;64:1056\u201361. https:\/\/doi.org\/10.2967\/jnumed.123.265391.","journal-title":"J Nuclear Medicine: Official Publication Soc Nuclear Med"},{"key":"6874_CR34","doi-asserted-by":"publisher","unstructured":"Kim C, Liu SV, Subramaniam DS, Torres T, Loda M, Esposito G, et al. Phase I study of the (177)Lu-DOTA(0)-Tyr(3)-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung. J Immunother Cancer. 2020;8. https:\/\/doi.org\/10.1136\/jitc-2020-000980.","DOI":"10.1136\/jitc-2020-000980"},{"key":"6874_CR35","doi-asserted-by":"publisher","unstructured":"Aicher A, Sindrilaru A, Crisan D, Thaiss W, Steinacker J, Beer M, et al. Short-Interval, low-dose peptide receptor Radionuclide Therapy in Combination with PD-1 checkpoint immunotherapy induces remission in immunocompromised patients with metastatic Merkel Cell Carcinoma. Pharmaceutics. 2022;14. https:\/\/doi.org\/10.3390\/pharmaceutics14071466.","DOI":"10.3390\/pharmaceutics14071466"},{"key":"6874_CR36","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/(SICI)1097-0215(19990924)83:1<121::AID-IJC21>3.0.CO;2-F","volume":"83","author":"ST Cheung","year":"1999","unstructured":"Cheung ST, Huang DP, Hui AB, Lo KW, Ko CW, Tsang YS, et al. Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int J Cancer. 1999;83:121\u20136.","journal-title":"Int J Cancer"},{"key":"6874_CR37","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1007\/s00259-021-05633-4","volume":"49","author":"J Shi","year":"2022","unstructured":"Shi J, Xue Z, Tan KV, Yuan H, Tsang ACM, Tsao SW, et al. Longitudinal evaluation of five nasopharyngeal carcinoma animal models on the microPET\/MR platform. Eur J Nucl Med Mol Imaging. 2022;49:1497\u2013507. https:\/\/doi.org\/10.1007\/s00259-021-05633-4.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06874-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-06874-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06874-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T09:05:42Z","timestamp":1732611942000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-06874-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,15]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["6874"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-06874-9","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,15]]},"assertion":[{"value":"6 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving human participants were carried out in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any experiments with animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"X Chen is co-founder of the Yantai LNC Biotechnology. The other authors declare that they have no potential conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}